title: [Cardiovascular risk in diabetes mellitus and hypertension in Spain. The CORONARIA study].
abstract: OBJECTIVE
  Diabetes mellitus is a prevalent disease with high cardiovascular mortality. Treatment of risk factors can reduce the associated cardiovascular risk. The CORONARIA study included 7253 patients with high risk systemic hypertension from different regions of Spain. The aim of this study was to analyze the cardiovascular risk (CR) of diabetic patients at baseline and after one-year follow-up.
  
  
  METHODS
  A total of 2105 (29%) patients with type 2 diabetes and systemic hypertension are included in the CORONARIA study. The CR profile is evaluated at baseline and after treatment of systemic hypertension with amlodipine (5-10 mg), while other cardiovascular risk factors were also treated. Data were compared with non diabetics.
  
  
  RESULTS
  Patients with systemic hypertension in Spain show a very high prevalence of diabetes (29%); it is higher in women than men (p<0.05) and higher in secondary prevention than primary prevention (p<0.05). Prevalence diabetes was higher in Murcia, Andalucía, Extremadura and Comunidad Valenciana, and lower in Madrid and País Vasco than the Spanish mean. The CR in primary prevention was significantly higher in diabetics than in non-diabetics (female: 22.9% vs 12.3% in Framingham, and 10.1% vs 5.2% in REGICOR; male: 39.9% vs 27.8% in Framingham and 15.7% vs 10.3% in REGICOR). After one year treatment, cardiovascular risk decreased significantly in both groups of patients, but it did more in diabetics (Framingham: -11.6% vs -6.7%; REGICOR: -5.3% vs -2.8%).
  
  
  CONCLUSIONS
  Most patients with diabetes and systemic hypertension did not have an adequate control of CR factors and presented a high cardiovascular risk. Treatment reduced the CR significantly in a greater proportion of diabetic than non diabetic-patients.
authors.affiliation: Unidad de Cardiocirculatorio, Centro de Investigación, Hospital Universitario La Fe, Avda. Camapnar 21, 46019 Valencia, Spain.
authors.forename: Juan
authors.initials: J
authors.lastname: Cosín Aguilar
authors.forename: Luis
authors.initials: L
authors.lastname: Rodríguez Padial
authors.forename: Amparo
authors.initials: A
authors.lastname: Hernándiz Martínez
authors.forename: Rosa
authors.initials: R
authors.lastname: Arístegui Urrestarazu
authors.forename: Xavier
authors.initials: X
authors.lastname: Masramón Morell
authors.forename: Beatriz
authors.initials: B
authors.lastname: Armada Peláez
authors.forename: Amparo
authors.initials: A
authors.lastname: Aguilar Llopis
authors.forename: José L
authors.initials: JL
authors.lastname: Zamorano Gómez
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000453:epidemiology*; D003924:Diabetes Mellitus, Type 2 / Q000453:epidemiology / Q000517:prevention & control*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000453:epidemiology / Q000517:prevention & control*; D008297:Male; D012307:Risk Factors; D013030:Spain / Q000453:epidemiology
chemical_list: D000959:Antihypertensive Agents